Results 201 to 210 of about 348,034 (261)

Noninvasive Characterization of Tumor Heterogeneity in HNSCC: From Clinical Utility to Biological Correlates

Advanced Science, EarlyView.
This study establishes a CT‐based radiomics framework to quantify intratumoral heterogeneity (ITH) in HNSCC. Using unsupervised clustering, tumor ROIs and VOIs are analyzed to calculate 2D/3D ITH scores. The score shows strong predictive value for prognosis and immunotherapy response, and is associated with tumor metabolism and immune microenvironment,
Xinwei Chen, Rui Liu, Yuan Zhou, Yin Xiao, Chengmin Feng, Lin Chen, Yanshi Li, Mengna Wang, Zhaobo Cheng, Yuxi Luo, Long Liu, Lijing Niu, Yue Xiang, Juan Peng, Guohua Hu, Min Pan   +15 more
wiley   +1 more source

Structural basis of Fumosorinone-mediated allosteric inhibition of PTP1B for cancer immunotherapy. [PDF]

Commun Biol
Zhang J, Lin L, Gong N, Li W, Liu Y, Sundarraj R, Li Y, Dong M, Ma J, Woycechowsky K, Mei K, Ge Y, Yuchi Z, Luo D.   +13 more
europepmc   +1 more source

SSR4 sustains Tertiary Lymphoid Structures by Regulation Quality Control of N‐linked Glycosylation During B‐cell Differentiation Into Plasmacyte in Colorectal Cancer

Advanced Science, EarlyView.
SSR4, a TRAP component induced in B cells, governs BAFFR N‐glycosylation via DDOST to sustain NF‐κB signaling, B‐cell differentiation, and TLS maturation. Its loss impairs anti‐tumor immunity, while overexpression improves antibody glycosylation and ADCC, revealing a critical regulator for cancer immunotherapy.
Wei Zhao, Youcai Zhao, Haiyang Li, Bowen Yang, Siyan Lu, Xueting Fu, Caixia Zhang, Yirong Chen, Xiaofeng Bian, Xinghua Ma, Xiaobing Yang, Bin Wang, Yuan Fang, Lulu Yang, Yelin Zhao, Shuli Zhao   +15 more
wiley   +1 more source

Oncolytic myxoma virus and engineering strategies for advanced cancer immunotherapy. [PDF]

iScience
Trujillo Yeriomenko AD, Isaeva AS, Idota EE, Zhivoderov SP, Yurkov SG, Malogolovkin AS.   +5 more
europepmc   +1 more source

NAT10‐Mediated ac4C Modification of circANKRD12 Reprograms the Tumor Microenvironment

Advanced Science, EarlyView.
NAT10‐dependent acetylation of circANKRD12 drives translation of the circANKRD12_354aa protein, which binds HDAC2 to stabilize c‐Myc via deubiquitination, promoting multiple myeloma (MM) cell proliferation. Concurrently, the circANKRD12‐HDAC2 axis suppresses H3ac‐mediated transcription of IFN‐γ, TNF‐α, and GZMB in NK cells, leading to NK cell ...
Jiale Zhang, Hui Shi, Chen Wang, Zihao Liu, Lianxin Zhou, Xinyu Lv, Mengjie Guo, Ye Yang, Chunyan Gu   +8 more
wiley   +1 more source

Initiation of Tertiary Lymphoid Structures for Cancer Immunotherapy. [PDF]

Research (Wash D C)
Zou JY, Li ZT, Wang ZC, Li H, Sun ZJ.
europepmc   +1 more source

PGK1 Suppresses CD8+ T Cell‐Mediated Antitumor Immunity Through CCL2/CCR2/Tumor‐Associated Macrophages Axis in Hepatocellular Carcinoma

Advanced Science, EarlyView.
PGK1 in tumor cells upregulates CCL2 expression through activation of the AKT/GSK‐3β/β‐catenin signaling axis, thereby promoting the recruitment and M2 polarization of TAMs and ultimately impairing the infiltration and activation of CD8+ T cells within the HCC tumor microenvironment. ABSTRACT Patients with advanced hepatocellular carcinoma (HCC) have a
Xi Liu, Jianpeng Liu, Zhihao Zhang, Xizhi Yu, Junjie Qian, Limin Ding, Qinchuan Wu, Zhe Yang, Xing‐Yu Luo, Xinjiang Ding, Rong Su, Xiaobo Yu, Yiting Qiao, Shengyong Yin, Haiyang Xie, Lin Zhou, Yuanxing Liu, Shusen Zheng   +17 more
wiley   +1 more source

Mitochondrial Carrier SLC25A13 Drives Ferroptosis Resistance and Immune Evasion via a STAT3–IFI6 Circuit in Breast Cancer

Advanced Science, EarlyView.
SLC25A13 is identified as an immunometabolic driver of triple‐negative breast cancer that sustains ferroptosis resistance and immune evasion through a STAT3–IFI6 circuit. Pharmacologic degradation of SLC25A13 restores ferroptosis sensitivity and enhances anti‐PD‐1 efficacy, highlighting a strategy to convert immune‐cold tumors into immunotherapy ...
Yingze Zhu, Yuhan Tang, Yingcui Chen, Zhuoqi Zhang, Yige Lu, Xinyue Wang, Qiyuan Shi, Wenhui Zhao, Hui Pang   +8 more
wiley   +1 more source

Bladder Cancer Immunotherapy in 2025: ALBAN, CREST, POTOMAC, and the Winner Is BCG! [PDF]

Int Braz J Urol
Reis LO.
europepmc   +1 more source

Novel Insights into the Role of circRNAs in Cancer Immunotherapy Resistance and Clinical Implications. [PDF]

Int J Mol Sci
Yang K, Zhang Y, Xiong J, Ai B, Han D, Chong X.   +5 more
europepmc   +1 more source